secwatch.observer — SEC 8-K summary
======================================

Issuer:     ORAGENICS INC (OGEN)
CIK:        0001174940
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001493152-26-021627
Event type: m_and_a
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oragenics signs LOI to license CardioDialysis from Sigyn Therapeutics for TBI
-----------------------------------------------------------------------------

- LOI grants Oragenics exclusive license for CardioDialysis blood purification tech in TBI and chronic neurodegenerative diseases.
- Consideration: 3,250,000 shares of preferred stock convertible 1:1 to common, plus 3% royalty for 6 years post-FDA clearance.
- Target closing within 90 days; Sigyn exclusivity during that period; subject to due diligence, board approvals, and NYSE American rules.
- Oragenics also advancing ONP-002 (Phase IIa intranasal neurosteroid); combined approach targets TBI inflammation on both sides of BBB.
- No FDA-approved pharmacological treatment for concussion/mTBI; 69 million brain injuries occur annually worldwide.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1174940/000149315226021627/0001493152-26-021627-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1174940/000149315226021627/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-021627

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer